AstraZeneca Annual Review 2005 - AstraZeneca Annual Reports

37CONSOLIDATED INCOME STATEMENTFOR THE YEAR ENDED 31 DECEMBER2005 2004 2003$m $m $mSales 23,950 21,426 18,849Cost of sales (5,356) (5,193) (4,463)Distribution costs (211) (177) (162)Research and development (3,379) (3,467) (3,012)Selling, general and administrative costs (8,695) (8,268) (7,393)Other operating income 193 226 188Operating profit 6,502 4,547 4,007Profit on sale of interest in joint venture – 219 –Finance income 665 532 381Finance expense (500) (454) (311)Profit before tax 6,667 4,844 4,077Taxation (1,943) (1,161) (1,033)Profit for the period 4,724 3,683 3,044Attributable to:Equity holders of the Company 4,706 3,664 3,022Minority interests 18 19 22Basic earnings per $0.25 Ordinary Share $2.91 $2.18 $1.77Diluted earnings per $0.25 Ordinary Share $2.91 $2.18 $1.77Weighted average number of Ordinary Shares in issue (millions) 1,617 1,673 1,709Diluted average number of Ordinary Shares in issue (millions) 1,618 1,675 1,712Dividends declared and paid in the period 1,676 1,408 1,244All activities were in respect of continuing operations.CONSOLIDATED STATEMENT OF RECOGNISED INCOME AND EXPENSEFOR THE YEAR ENDED 31 DECEMBER2005 2004 2003$m $m $mProfit for the period 4,724 3,683 3,044Foreign exchange adjustments on consolidation (1,052) 744 1,267Available for sale (losses)/gains taken to equity (10) 31 1Actuarial loss for the period (35) (179) (240)Tax on items taken directly to reserves (25) 416 139(1,122) 1,012 1,167Total recognised income and expense for the period 3,602 4,695 4,211Attributable to:Equity holders of the Company 3,595 4,690 4,186Minority interests 7 5 25Tax on items taken directly to reserves in 2004 includes a credit of $357m in respect of foreign exchange losses in 2000.$m means millions of US dollars